CDK6 and hepatocellular carcinoma: For example, lenvatinib is a multitargeted kinase inhibitor in clinical trials for hepatocellular carcinoma, and XO44 was used to understand potential resistance that may emerge to the candidate through kinase rewiring processes, as seen for other kinase inhibitor drugs.78 Through quantitative chemoproteomic profiling using XO44 it was revealed that CDK6 was significantly upregulated in lenvatinib-resistant HCC cells compared to mock controls, highlighting its role in the regulation of resistance.